One arm, Open label, Interventional, non-comparative Study to assess Changes in Lipids and Lipoproteins in HIV infected Women with Hyperlipidemia after Switch from boosted Protease Inhibitors to Raltegravir
Phase of Trial: Phase II
Latest Information Update: 22 Sep 2016
Price : $35 *
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics
- 25 May 2016 Status changed from recruiting to completed.
- 06 Jun 2015 Planned End Date changed from 1 Dec 2014 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
- 06 Jun 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Feb 2016 as reported by ClinicalTrials.gov record.